Back to Search
Start Over
Cardurion Pharmaceuticals Presents Positive Clinical Results from CARDINALHF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients With Heart Failure
- Source :
- Business Wire. May 11, 2024
- Publication Year :
- 2024
-
Abstract
- - PDE9 inhibitor, CRD-740, demonstrated favorable safety profile and achieved statistical significance for the trial's primary endpoint, median increase in plasma cyclic guanosine monophosphate (cGMP) - - This clinical trial [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire
- Publication Type :
- News
- Accession number :
- edsgcl.793411339